Howard recently joined Ultragenyx, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, and is responsible for leading the company’s global finance, accounting, corporate strategy and investor relations functions.
He joined Ultragenyx from Vir Biotechnology, where he served as CFO and as a member of Vir’s founding management team, guiding the rapid transformation of Vir to a public, commercial-stage organization. Prior to Vir, Howard was at Biogen where he served first as vice president, strategic corporate finance and then as vice president, business planning. Previously, he held positions of increasing responsibility as a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Company, and as an equity research analyst in the Life Sciences group at UBS Group AG.
Howard received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.
He joined Ultragenyx from Vir Biotechnology, where he served as CFO and as a member of Vir’s founding management team, guiding the rapid transformation of Vir to a public, commercial-stage organization. Prior to Vir, Howard was at Biogen where he served first as vice president, strategic corporate finance and then as vice president, business planning. Previously, he held positions of increasing responsibility as a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Company, and as an equity research analyst in the Life Sciences group at UBS Group AG.
Howard received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.